Imaging and Gait Analysis in FSHD Patients

Key facts

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Principal Investigator

Enzo Ricci

Fondazione Policlinico Universitario A. Gemelli, IRCCS

Enrollment

40 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• UOC Neurologia, Rome, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Facioscapulohumeral dystrophy

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07086521
  Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)
  Restem, LLC.
• RECRUITINGPHASE3NCT07038200
  A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
  Avidity Biosciences, Inc.
• RECRUITINGPHASE1, PHASE2NCT06907875
  A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
  Epicrispr Biotechnologies, Inc.
• RECRUITINGNCT06911190
  Ten Year Follow-up in FSHD: the FOCUS 3 Study
  Radboud University Medical Center
• RECRUITINGNCT07409142
  BetterLife FSHD: A Patient-driven Health and Research Platform
  FSHD Society
• ENROLLING BY INVITATIONPHASE2NCT06547216
  Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
  Avidity Biosciences, Inc.
• RECRUITINGNANCT06600308
  Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular Dystrophies
  Centre Hospitalier Universitaire Dijon
• ACTIVE NOT RECRUITINGPHASE2NCT06222827
  Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1
  Centre Hospitalier Universitaire de Nice

See all trials for Facioscapulohumeral dystrophy →